Recurrent Respiratory Papillomatosis Epidemiology

• Recurrent Respiratory Papillomatosis (RRP) is a rare yet complex condition marked by benign tumor growth, or papillomas, within the respiratory tract, especially in the larynx, trachea, and bronchi. The disease is mainly driven by infection with human papillomavirus (HPV), particularly types 6 and 11. In 2023, the 7MM population with RRP is estimated at approximately 25,700.
• According to DelveInsight analysis, in 2023, the US represented the largest share of the diagnosed RRP population within the 7MM, accounting for 66% of the total cases.
• RRP represents a growing health concern in the United States, with its prevalence rising over recent decades. DelveInsight estimates indicate that among the different age groups in 2023, the largest number of cases is in those aged 18 years and above (~15,816), followed by those aged 0─8 years (~660), and the smallest number of cases is in the 9─17 years age group (~507).
• In 2023, Japan reported approximately 2,474 diagnosed prevalent cases of RRP among which ~2,276 cases were associated with HPV 6 and/or HPV 11, while ~198 cases were linked to other high-risk subtypes such as HPV-16, 18, 31, 33, 39, and other factors. This data highlights that the majority of RRP cases in Japan are predominantly driven by HPV 6 and 11, with a significantly smaller proportion attributable to other high-risk HPV subtypes and additional factors. The disparity in case numbers underscores the critical role of HPV 6 and 11 in the etiology of RRP within the Japanese population.

DelveInsight’s “Recurrent Respiratory Papillomatosis Epidemiology Forecast – 2034” report delivers an in-depth understanding of Recurrent Respiratory Papillomatosis (RRP), historical and forecasted epidemiology of Recurrent Respiratory Papillomatosis (RRP) in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

Recurrent Respiratory Papillomatosis (RRP) Understanding

Recurrent Respiratory Papillomatosis (RRP) Overview

RRP is a rare, chronic disease characterized by the growth of benign tumors, known as papillomas, in the respiratory tract, particularly affecting the larynx and vocal cords. These growths, caused by human papillomavirus (HPV) types 6 and 11, can obstruct the airway, leading to voice changes, breathing difficulties, and recurring surgeries. RRP manifests in two forms: juvenile-onset, typically diagnosed in early childhood, and adult-onset, appearing later in life. Despite its benign nature, RRP is challenging to manage due to its recurrent nature and the lack of a definitive cure.

Recurrent Respiratory Papillomatosis (RRP) Diagnosis

RRP diagnosis involves a combination of clinical evaluation, endoscopic examination, and histopathological analysis. A laryngoscopy or bronchoscopy is commonly used to visualize and assess the presence of papillomas in the respiratory tract. Biopsy samples are analyzed to confirm HPV infection and differentiate RRP from other conditions.

Diagnosing RRP can be challenging due to its variable presentation and overlap with other respiratory disorders. Additionally, the disease’s intermittent nature and the potential for misdiagnosis or delayed diagnosis further complicate accurate identification, necessitating a high index of suspicion and comprehensive evaluation by specialized clinicians.

Further details related to diagnosis are provided in the report...

Recurrent Respiratory Papillomatosis (RRP) Epidemiology

For the purpose of designing the patient-based model for RRP, the report provides historical as well as forecasted epidemiology segmented by Diagnosed Prevalent Cases of RRP, Age-specific Diagnosed Prevalent Cases of RRP, and Etiology-specific Diagnosed Prevalent Cases of RRP in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2021 to 2034.

• In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of RRP in Japan were nearly 2,474 in 2023.
• The total diagnosed prevalent cases of RRP in the US comprised approximately 16,980 in 2023 and are projected to increase during the forecast period.
• As per DelveInsight’s estimates, the US alone accounts the highest number of total diagnosed prevalent cases, of RRP in the 7MM, followed by EU4 and the UK and Japan, contributing to 24% and 10% of all RRP cases respectively.
• In 2023, Japan reported the highest number of RRP cases among adults aged 18 and older (~2,400), followed by adolescents aged 9─17 years (~50). The smallest number of cases was in children aged 0─8 years, totaling ~25.
• In 2023, the EU4 and the UK reported a total of ~6,242 diagnosed prevalent cases of RRP, with approximately 5,742 cases associated with HPV 6 and/or HPV 11, and ~500 cases linked to other high-risk subtypes like HPV-16, 18, 31, 33, and 39. The high number of cases related to HPV 6 and 11 reflects the predominant role these strains play in RRP, as they are the primary etiological agents. The relatively lower number of cases associated with other high-risk HPV subtypes indicates their less frequent but still significant contribution to RRP, underscoring the need for targeted interventions and monitoring of HPV-related factors in managing the disease.
• In 2023, Germany reported the highest number of diagnosed prevalent RRP cases in the EU4 and the UK, totaling nearly 1,684. France followed with approximately 1,370 cases, Italy had ~1,220, the UK reported ~1,022, and Spain had the fewest with ~944 cases. This distribution highlights varying disease burden across European countries.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.

DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the University of Chicago Medicine, US; Massachusetts General Hospital, US; University Medical Center Göttingen, Göttingen, Germany;  Strasbourg University Hospital, Strasbourg, France; University of Genoa, Genova, Italy; University of Barcelona, Spain; Sandwell and West Birmingham Hospitals NHS Trust, UK; Osaka University Graduate School of Medicine, Suita, Japan; and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Explore the evolving Recurrent Respiratory Papillomatosis Market trends, key players, and future outlook.

Scope of the Respiratory Papillomatosis Epidemiology Report

• The report covers a segment of executive summary, descriptive overview of RRP, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Recurrent Respiratory Papillomatosis (RRP) Report Insights

• Respiratory Papillomatosis Patient Population
• Country-wise Epidemiology Distribution
• Total Diagnosed Prevalent Cases of Parkinson’s Disease
• Gender-specific Diagnosed Prevalent Cases of Parkinson’s Disease
• Age-specific Diagnosed Prevalent Cases of Parkinson’s Disease
• Stage-specific Diagnosed Prevalent Cases of Parkinson’s Disease
• Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease
• Diagnosed Prevalent Cases of MCI due to Parkinson's Disease 

Recurrent Respiratory Papillomatosis (RRP) Report Key Strengths

• 11 years Forecast
• The 7MM Coverage
• Parkinson's Disease Epidemiology Segmentation

Recurrent Respiratory Papillomatosis (RRP) Report Assessment

• Current Diagnostic Practices Patient Segmentation

Respiratory Papillomatosis Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of RRP? What will be the growth opportunities across the 7MM concerning the patient population of RRP?
• What is the historical and forecasted RRP patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Why is the diagnosed prevalent cases of RRP in Japan lower than the US?
• Which country has a high patient share for RRP?

Reasons to Buy Respiratory Papillomatosis Epidemiology Report:

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the RRP prevalence cases in varying geographies over the coming years.
• A detailed overview of Age-specific diagnosed prevalence of RRP.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1.         What is the forecast period covered in the report?

The RRP Epidemiology report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2.         Out of all EU4 countries and the UK, which country had the highest population of P Recurrent Respiratory Papillomatosis (RRP) cases in 2023?

The highest cases of RRP was found in the Germany among EU4 and the UK in 2023.

3.         How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4.         Out of all 7MM countries, which country had the highest population of RRP cases in 2023?

The highest cases of RRP were found in the US among the 7MM in 2023.